Package 59572-102-01

{"route": ["INTRAVENOUS", "SUBCUTANEOUS"], "spl_id": "8cba79e2-11fa-4eb9-87e7-827ca781fbf3", "openfda": {"nui": ["N0000000233", "N0000175595"], "unii": ["M801H13NRU"], "rxcui": ["485246", "545206"], "spl_set_id": ["3495a71a-cc04-4776-851f-f185956f32af"], "pharm_class_epc": ["Nucleoside Metabolic Inhibitor [EPC]"], "pharm_class_moa": ["Nucleic Acid Synthesis Inhibitors [MoA]"], "manufacturer_name": ["Celgene Corporation"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (59572-102-01)", "package_ndc": "59572-102-01", "marketing_start_date": "20040705"}], "brand_name": "VIDAZA", "product_id": "59572-102_8cba79e2-11fa-4eb9-87e7-827ca781fbf3", "dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION", "pharm_class": ["Nucleic Acid Synthesis Inhibitors [MoA]", "Nucleoside Metabolic Inhibitor [EPC]"], "product_ndc": "59572-102", "generic_name": "azacitidine", "labeler_name": "Celgene Corporation", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "VIDAZA", "active_ingredients": [{"name": "AZACITIDINE", "strength": "100 mg/1"}], "application_number": "NDA050794", "marketing_category": "NDA", "marketing_start_date": "20040705", "listing_expiration_date": "20261231"}